How to select the right first indication for your platform technology?

In this SPARK Europe Webinar, Dr. Peter Nestorov will talk about Scailytes’ experience and approach when selecting their initial and follow up indications based on various parameters.


In this SPARK Europe Lecture, Dr. Peter Nestorov (Co-founder and CEO of Scailyte) will talk about his experience and approach selecting the initial and follow up indications. ScaiVision is an AI platform using complex multi-omics data to extract composite biomarkers associated with different cell populations and relevant clinical outcomes.

Online via zoom | Please register here!

SPARK Europe is the joint network of SPARK sites all over Europe including Israel: SPARK-BIH, SPARK Finland, SPARK FLI, SPARK Norway, SPARK Poland and SPARK Tel Aviv. European SPARK programs are members of SPARK Global network. The purpose of SPARK programs is to provide the education and mentorship necessary to advance research discoveries from the bench to the bedside, hence to increase the maturity of academic and clinical discoveries towards practical solutions that address unmet needs in the life science and health tech space. The program follows the same principles that have been the cornerstones of SPARK at Stanford since it was established by Professor Daria Mochly-Rosen and Kevin Grimes in 2006 for advancing new biomedical research discoveries into promising new treatments for patients.


SPARK-BIH is a member of the SPARK Global network